Global Diagnostic Biomarker, Forecast, Market Analysis, Global Industry SizePosted by pranshu@95 on July 3rd, 2019 “Orion Market Research (OMR), recently published a market research report on the global diagnostic biomarker market. According to the OMR analysis, the global diagnostic biomarker market is growing at a significant rate during 2018-2023. The global diagnostic biomarker market has witnessed a significant growth due to high number of research institutes focused on diagnostic biomarkers. The global diagnostic biomarker is segmented on the basis of application, diagnostic technique and end-user. The report provides detailed and insightful chapters on market overview, key findings, strategic recommendations, market estimations, market determinants, patent analysis, key company analysis, market insights, company profiling, market segmentation, geographical analysis and analyst insights. Full report of global Diagnostic biomarker market is available at https://www.omrglobal.com/industry-reports/diagnostic-biomarker-market/ “The researches by the different research institutes that are going presently has turned to the diagnosis of the diseases such as cancer, for developing new biomarkers. Presently, the scientists are focusing on the gene expression for detecting the results of therapy process. Recently, National Cancer Institute (NCI) sponsored Trial Assigning Individualized Option for treatment (Rx), or TAILORx. During the test there were several women that were diagnosed recently with lymph node-negative, hormone receptor was positive during test. The number of women observed with the lowest of 21-gene recurrence score were low. The biomarkers test is being utilized to find the risk factor of reoccurrence of the breast cancer. During January 2015 there was an investment made by the Precision Medical Initiative of million to the National Cancer Institute. The investment was made to recognize the different genomic drivers in cancer and to develop new approaches for diagnosis of the cancer. The development of cancer biomarker for the treatment and therapy has been focused on more. Various research work is going on to improve the accuracy of the biomarkers and results response. The National Cancer Institute in March 2016 had earmarked .5 million for funding for the establishment of laboratories with an aim to advance research on biomarkers and biomarker assays for various cancers such as of the prostate, lung, breast, and genitourinary organs. The Biomarker Developmental Laboratories (BDLs) will be a part of the early detection research network of the NCI. Within this funding, the NCI’s aim is to fund eight to ten BDLs that will be involved in developing and characterizing the new biomarkers and assays or refining the existing ones. Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles. Media Contact: Like it? Share it! More by this author |